N/A N=394 Observational Study on 2-chloroprocaine Hydrochloride 1%
Neurological Complication, in Particular TNS or CES
Primary: Number of Participants With Adverse Events — 9; 5 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=84 A Study of OPC-41061 Orally Disintegrating (OD) Tablets Using 2 Different Formulations and 2 Dosing Regimens in Healthy Adult Male Subjects
Healthy Adult Male
Primary: Maximum Plasma Concentration (Cmax) of Tolvaptan — 131; 149; 125; 203 ng/mL
N/A N=18 WallFlex Esophageal Fully Covered (FC) Benign Anastomotic Stricture
Refractory Anastomotic Esophageal Strictures
Primary: Number of Dilation Procedures — 5.4; 2.4 Dilation procedures — p=0.159
N/A N=14 Cognitive Recovery After Electroconvulsive Therapy and General Anesthesia
Depression · Delirium · Seizures
Primary: Change in Cognitive Function During Recovery: Rate of Recovery — 3.5; 6.3; 24.7; 9.7 inverse hours — p=0.016
Phase 2 N=10 Low-dose Intra-arterial Bevacizumab for Edema and Radiation Necrosis Therapeutic Intervention (LIBERTI)
Radiation Necrosis
Primary: Change in Radiation Necrosis and Cerebral Edema After a Single Treatment of Low Dose Intra-arterial Avastin (Bevacizumab) — 86.8; 38.6; 32.6; 14.5 cm^3 — p=0.012
N/A N=38 Sensor-controlled Digital Game for Heart Failure Self-management
Heart Failure
Primary: Number of Days With Weight-monitoring on Sensor Logs at 6 Weeks — 35.8; 32.9 days
N/A N=451 Randomized Controlled Trial of a Risk Reframing Tool to Change Mothers' Parenting Associated With Children's Risky Play
Risk Assessment · Parenting
Primary: Change in Tolerance of Risk in Play Scale (TRiPS) — 0.05; -0.14; 0.18; -0.09 score on a scale
N/A N=1,164 Drug Use Investigation of Selara Tablets (an Investigation for Chronic Heart Failure)
Chronic Heart Failure
Primary: Percentage of Participants With Adverse Drug Reactions in Chronic Heart Failure Participants With Moderate Renal Impairment — 9.49; 1.58 Percentage of Participants
Phase 2 N=127 Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
Tourette Syndrome
Primary: Change From Baseline to Week 12 in the Yale Global Tic Severity Scale (YGTSS) Total Tic Score (TTS) — -6.8; -8.9 score on a scale — p=0.1768
N/A N=40 TRI-REPAIR: TrIcuspid Regurgitation RePAIr With CaRdioband Transcatheter System
Tricuspid Valve Insufficiency · Tricuspid Regurgitation · Tricuspid Valve Regurgitation
Primary: Major Serious Adverse Events (MSAEs) and Serious Adverse Device Effects (SADE) — 3; 1 Participants
N/A N=41 Wound Vac Bandage Comparison After Spinal Fusion
Neuromuscular Scoliosis
Primary: Number of Participants With Wound Dehiscence or Infection — 0; 0 Participants
Phase 2 N=58 Hydroxyurea Management in Kids: Intensive Versus Stable Dosage Strategies
Sickle Cell Anemia
Primary: Number of Patients Enrolled. — 58 Participants
N/A N=187 Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy
Central Nervous System Tumor, Pediatric · Chemotherapy-induced Nausea and Vomiting · Unspecified Childhood Solid Tumor, Protocol Specific
Primary: Efficacy of Treatment on CIN During Acute Phase of Chemotherapy — 37; 41; 17; 8 Participants
N/A N=452 Financial Incentives to Increase Pediatric HIV Testing
HIV
Primary: Number of Participants Who Present Children for HIV Testing — 31; 31; 44; 51 Participants
Phase 3 N=224 Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children
Pediatric Growth Hormone Deficiency
Primary: Annual Height Velocity in Main Study Phase — 10.10; 9.78 cm/year